

## PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/125669>

Please be advised that this information was generated on 2017-12-06 and may be subject to change.

METHODOLOGY

Open Access

# Molecular detection and quantification of *Plasmodium falciparum*-infected human hepatocytes in chimeric immune-deficient mice

Lander Foquet<sup>1</sup>, Cornelus C Hermsen<sup>2</sup>, Geert-Jan van Gemert<sup>2</sup>, Louis Libbrecht<sup>3</sup>, Robert Sauerwein<sup>2</sup>, Philip Meuleman<sup>1</sup> and Geert Leroux-Roels<sup>1\*</sup>

## Abstract

**Background:** Chimeric mice with humanized livers represent a promising tool for infections with *Plasmodium falciparum* to evaluate novel methods for prevention and treatment of pre-erythrocytic stages. Adequate assessment of hepatic infections is generally compromised by the limited number of human hepatocytes infected by developing parasites.

**Methods:** A qPCR-based method has been developed that sensitively and reliably detects *P. falciparum* liver stage infection of humanized mice and quantitatively expresses the results as the number of parasites per human hepatocyte.

**Results:** This assay allows for detection of liver stage parasites after challenging humanized mice with infected mosquito bites or after intravenous injection with sporozoites. The sensitivity of the protocol, which comprises approximately 25% of the total chimeric liver, allows for the detection of a single infected hepatocyte in the analysed tissue.

**Conclusions:** This method allows for the detection and quantification of *P. falciparum* parasites in chimeric mice repopulated with human hepatocytes. It will be a useful tool when studying the *in vivo* therapeutic and/or prophylactic qualities of novel compounds, small molecules or antibodies directed against the liver stage of *P. falciparum* infections.

**Keywords:** Humanized mouse model, Malaria, *Plasmodium falciparum*, Sporozoite, Liver stage, *in vivo*, qPCR

## Background

*Plasmodium falciparum* is responsible for most of the estimated 219 million clinical malaria cases that were reported in 2010 [1]. Rodent models for malaria (e.g. *Plasmodium berghei* in mice) are used to test possible new anti-malarial drugs [2] and candidate vaccines [3] before entering the clinical phase of downstream product development [4]. However, significant differences between rodent models and human malaria [5] necessitate the availability of alternative models to study *P. falciparum*. Humanized mouse models have been developed to study either blood stage or liver stage of malaria. By engrafting human red blood cells (huRBC) into immunodeficient mice, a high percentage of huRBC in mouse peripheral

blood can be obtained [6]. Subsequent injection of infected human erythrocytes results in a blood stage infection that can be maintained for several days and allows for the *in vivo* testing of new therapies against blood stage infection [7,8]. The liver stage of malaria can be studied in human liver chimeric mice. These models are based on the ability of immunodeficient mice with a severe liver disease to accept a graft of human hepatocytes and allow these cells to home into the diseased mouse liver where their expansion leads to high degrees of repopulation with human hepatocytes. Immune deficient mice have acquired severe liver disease through the transgenic overexpression of urokinase-type plasminogen activator in uPA<sup>+/+</sup>-SCID mice or a knockout of fumarylacetoacetate hydrolase (FAH) in FRG (Fah<sup>-/-</sup>Rag2<sup>-/-</sup>IL2-Rg<sup>-/-</sup>) mice [9-13]. These humanized mice can subsequently be infected with *P. falciparum* sporozoites [14,15] and full parasite maturation in

\* Correspondence: geert.lerouxroels@ugent.be

<sup>1</sup>Center for Vaccinology, Ghent University and University Hospital, De Pintelaan 185, Ghent 9000, Belgium

Full list of author information is available at the end of the article

human hepatocytes can be achieved, but emerging parasites cannot successfully infect murine erythrocytes [16]. The Center for Vaccinology (CEVAC) has been successful in producing chimeric uPA<sup>+/+</sup>-SCID mice with a high degree of repopulation with human hepatocytes to study hepatitis B and C virus (HBV and HCV) infections [17-20]. Recently, transfer of human hepatocytes was started in FRG mice that originate from Marcus Grompe's laboratory [10].

Several methods are available to detect parasites in an infected humanized mouse model. Immune staining techniques do visualize infected hepatocytes but quantification and comparison of animals with different degrees of human hepatocyte repopulation remains difficult. Moreover, these techniques are labour-intensive with low throughput and limited sensitivity [15,21]. Alternatively, a successful infection of the chimeric mouse liver can be directly visualized *in vivo* after challenge with a GFP-luciferase transgenic *P. falciparum* strain [22]. While enabling parasite detection without sacrificing the animal, this technique lacks the sensitivity to visualize early liver stage infection *in vivo* [23]. The lower sensitivity necessitates the infection of humanized mice by intravenous (IV) injection of up to 10<sup>6</sup> sporozoites, representing an unnaturally high number of parasites [22]. Therefore, a highly sensitive qPCR-based method was improved to detect and quantify hepatic infections of *P. falciparum*, after IV injection of sporozoites or following natural infection via mosquito bites.

## Methods

### Generation of humanized mice

Humanized uPA<sup>+/+</sup>-SCID mice were generated as previously described [9]. Briefly, within two weeks after birth cryopreserved primary human hepatocytes (approximately 10<sup>6</sup> cells/mouse, purchased from BD Gentest (Erembodegem, Belgium)) were injected in the spleens of uPA<sup>+/+</sup>-SCID mice [24]. Hepatocytes from the same donor were used to allow comparison between the different experiments. Between six weeks after transplantation and up to one week before the infection experiment, human albumin levels in mouse plasma were measured using Human Albumin ELISA Quantitation kit (Bethyl Laboratories Inc, Montgomery, TX, USA). Animals with human albumin levels >2 mg/mL were considered successfully engrafted and used for infection studies. All procedures were approved by the Animal Ethics Committee of the Faculty of Medicine and Health Sciences of the Ghent University.


### Parasite challenge

*Plasmodium falciparum* NF54 infected *Anopheles stephensi* mosquitoes were reared as described previously [25] at Radboud University (Nijmegen, Netherlands).

Chimeric mice were infected with sporozoites, either by mosquito bites or by injection in the retro-orbital venous plexus. To mimic a natural infection as closely as possible, humanized mice were exposed for 20 minutes to bites of 20 *P. falciparum*-infected mosquitoes that contained each on average 70,000 sporozoites in the salivary gland. Before exposure to the mosquitoes, abdomen and chest of the mice were shaven with electric clippers. Next mice were positioned on a cardboard box containing 20 infected mosquitoes (one box for each mouse). Successful blood feeding (mean: 17 mosquitoes) and sporozoite presence (100%) was confirmed by mosquito dissection after the challenge experiment [3,26]. To inject a defined number of parasites, sporozoites were extracted by hand dissection from the salivary glands of infected mosquitoes killed by ethanol spraying [23]. Mice were anaesthetised with 3% isoflurane in 0.5 L/min 100% O<sub>2</sub> and 150,000 salivary gland sporozoites in 100 µL RPMI 1640 (GIBCO) were injected in the retro-orbital venous plexus [27], because the extremely small diameter of the tail vein of humanized uPA<sup>+/+</sup>-SCID mice precludes intravenous injection.

### Isolation of DNA and quantitation of plasmodium falciparum and human hepatocyte DNA

Five days after infection mice were maximally bled (around 500 µL) and subsequently euthanized by cervical dislocation. The livers were carefully removed, cut into 12 standardized sections and stored in RNALater (Ambion) at 4°C until analysis (Figure 1). Of each section, exactly 25 mg (± 0.1 mg) tissue was taken for DNA extraction in 100 µL elution buffer with the High Pure PCR Template Preparation Kit (Roche). *Plasmodium falciparum* DNA levels were quantified using a highly sensitive qPCR assay [28]. Briefly, 5 µL DNA extract was added to 20 µL mastermix (LightCycler 480 Probes Master, Roche) containing *P. falciparum* 18SRNA gene-specific primers and a probe labelled with 6-carboxy-fluorescein (FAM) as a reporter and 6-carboxy-tetramethylrhodamine (TAMRA) as a quencher. *Plasmodium falciparum* standard curves were prepared by spiking DNA extracts from titrated samples of ring stage *P. falciparum*-infected erythrocytes (range 10–10,000 parasites (Pf) per 100 µL extract) with DNA extracts from a non-infected humanized liver. The detection limit was set at 0.2 Pf/5 µL extract, since the sensitivity of this standardized assay (20Pf/mL blood) correlates to 0.2 Pf/5 µL extract as shown in Figure 2. Because the reaction is performed in duplicate it is possible to detect 0.2 Pf in 10% of the total extract (if only one out of two reactions is positive). Since all 12 fragments are analysed separately but in an identical way it is possible to detect two Pf in 300 mg tissue (this if only one of twelve fragments is positive). To assess the



**Figure 1 Standardizing the sampling of humanized liver fragments.** Five days post-infection, mice are euthanized by cervical dislocation. The livers are carefully removed, rinsed in PBS and 12 standardized fragments (A-L) are prepared and placed in RNALater until further analysis.

repopulation of chimeric livers with human hepatocytes and to express the *P. falciparum* infection as a number of parasites per  $10^6$  human hepatocytes, employed a qPCR was employed as described by Alcoser *et al.*, that quantifies the relative amount of human and mouse cells in mixed tissues [29]. Briefly, 1  $\mu$ L DNA extract was added to 19  $\mu$ L mastermix (LightCycler 480 Probes Master, Roche) containing common primers that amplify a 215 bp region located in the human and mouse prostaglandin E receptor 2 (PTGER2) genes (Figure 3). The amplified region contains a non-homologous sequence which is targeted by two species-specific Taqman probes, each conjugated with a unique fluorescent tag (FAM and Cy5), which makes it possible to quantify the copy number and differentiate between mouse and human origin in duplex. Standard curves were prepared by DNA extraction from a titration of defined numbers of human PBMC and mouse splenocytes (Figure 2). Percentage calculation was verified by making various ratios of mouse and human DNA extracts.

#### Liver tissue specimens and histochemistry

Liver samples were fixed in formalin and slides were stained with haematoxylin-eosin following standard techniques as described [9].

## Results



#### Standardizing the sampling of humanized liver fragments


Injection of *P. falciparum* sporozoites in a chimeric mouse will result in infection of an unknown and low number of infected human hepatocytes distributed in a large background of non-infected mouse and human cells (Figure 4). Consequently, an analysis of the

complete liver by cell lysis and subsequent DNA extraction will result in a strong dilution of parasitic DNA and loss of sensitivity. Therefore, exactly 25 mg of liver tissue was sampled from 12 standardized sections (Figure 1) for DNA extraction in a volume of 100  $\mu$ L. Five  $\mu$ L of each extract was used in duplicate to measure the number of parasites by qPCR and 1  $\mu$ L to determine the fraction (percentage) of human hepatocytes in each fragment (Figure 2). This approach allowed for the analysis of several millions of human hepatocytes randomly distributed in each chimeric liver (Additional file 1: Table S1).

#### Measurement of parasites in humanized livers: standardization and quantification

Both presence of parasite [28] as well as mouse and human [29] DNA was determined in each fragment by qPCR (Figures 2 and 3). Since hepatocytes are frequently multinucleated [30], a histological examination was performed of humanized liver sections of two chimeric mice as described before [12,31]. Because less than 10% of both human and mouse hepatocytes displayed a multinucleated aspect (Figure 4), the calculation of the number of hepatocytes was not corrected. The ratio of human DNA *versus* [human DNA + mouse DNA] was multiplied by 1.7 because it is described [13,32] that only 60% of chimeric liver tissue consists of hepatocytes (40% are other cell types) (Additional file 1: Table S1). Calculating the percentage of human hepatocytes in the chimeric liver by using the qPCR data made it possible to compare the degree of repopulation by human hepatocytes of each liver fragment and each liver as a whole. The degree of repopulation measured in the separate fragments corresponds well with the average degree





**Figure 4 Histology and determination of polyploidy of a chimeric liver.** (A) A representative section of a chimeric liver (haematoxylin and eosin staining) showing the morphological differences between pale human hepatocytes (upper zone), diseased mouse parenchyma (middle zone) and healthy mouse parenchyma originating from mouse hepatocytes that have eliminated both uPA transgene copies, known as red nodules (lower zone). Detailed view of chimeric liver sections, showing human hepatocytes (B) none of which is multinucleated and mouse hepatocytes (C), one of which is binucleated (arrow). Original magnification A: 200 x, B and C: 400 x.

(Additional file 1: Table S1). Finally, the liver parasite burden, expressed as the number of parasites per million human hepatocytes was calculated by dividing the total number of parasites detected in the 12 samples derived from a chimeric liver by the total number of human hepatocytes in these samples (Figure 2 and Additional file 1: Table S1).

#### Comparison of different infection protocols

After the injection of 150,000 *P. falciparum* sporozoites in the retro-orbital venous plexus [14,15], infection of human hepatocytes was demonstrated in all mice (mean: 11,405.6 parasites per  $10^6$  human hepatocytes) using the analytical methods described above (Additional file 2: Table S2). In addition, humanized mice were exposed to 20 infected mosquitoes during 20 minutes [33]. Additional file 1: Table S1 shows that the ensuing infection can be detected in multiple samples (A-L) and is more comparable in the different animals irrespective of their degree of chimerism than when mice were challenged by injection of 150,000 *P. falciparum* sporozoites (mean: 1,503.1 parasites per  $10^6$  human hepatocytes). The observed lower variation in the liver parasite burden was not anticipated since mosquito bites lead to an unknown and variable parasite challenge [34].

#### Discussion

A method is presented to detect and quantify *P. falciparum* parasites in the livers of humanized mice following infection via intravenous injection of sporozoites or bites from infected mosquitoes. The approach combines a systematic analysis of 12 standardized liver sections from each chimeric liver to avoid sampling bias and sample dilution with the analytical sensitivities of qPCR methods to quantify parasite numbers and human hepatocyte content of each fragment.


Based on qPCR results obtained by sacrificing humanized mice at different time points, it is estimated that a single infected hepatocyte may contain approximately 20 parasites three days after infection and between 200 and 400 parasites five days after infection. Previous studies estimate that this number could rise even further to more than 30,000 parasites per infected hepatocyte at the end of the pre-erythrocytic stage, six to seven days after infection [15,35]. Humanized mice were sacrificed five days after infection because this leaves sufficient time for parasite DNA not confined to an infected human hepatocyte to be cleared, while this point in time is sufficiently remote from the beginning of the end of the liver stage at day 6 to prevent the release of merozoites from infected hepatocytes and subsequent clearance from the blood since these cannot infect mouse erythrocytes [15,28].

Analysis of multiple (12) samples from each liver increases the sensitivity of the method as compared to the analysis of a small sample taken from a homogenized whole liver. As few as two parasites (Pf) in 300 mg analysed tissue can be detected. Indeed, the latter approach may lead to a dilution that is possibly too high to detect DNA of parasites originating from only a few infected cells located within a limited zone of the liver. If one assumes that only one human hepatocyte was infected with *P. falciparum*, this would result in at least 200 Pf after five days. Since approximately one quarter of the total liver was analysed (the liver represents 9% of the total body weight), there was 25% chance that the infected hepatocyte is located within the tissue analysed. Since that hepatocyte would be present in one of the 12 fragments, this one fragment would contain at least 200 Pf. Given that the assay has a sensitivity of two parasites per fragment, the parasites enclosed in a single infected hepatocyte will be detected. This is considerably better than any other method currently available for the *in vivo* study of *Plasmodium falciparum* infection (e.g., histology, *in vivo* bioluminescence with luciferase expressing parasites, etc.).

Quantification of both human and mouse DNA in addition to *P. falciparum* DNA allowed for the determination of the degree (percentage) of human repopulation of each of the 12 mouse liver fragments (Additional file 1: Table S1). This approach differs from previous studies in which the degree of chimerism was calculated by determining the proportion of the liver parenchyma surface area that consisted of human hepatocytes based on immunohistochemical analyses of a series of liver sections [11,31,36]. Since hepatocytes are much larger than non-parenchymal cells, the area occupied by human hepatocytes will overestimate the fraction represented as cell numbers. The data show that the percentage of repopulation of a humanized mouse in different liver lobes is quite stable and does not significantly influence the infection with *P. falciparum* sporozoites (Additional file 2: Table S2). Figure 5 shows that the percentage human hepatocytes correlates well with the human albumin concentrations in chimeric mice ( $R = 0.57$ ;  $P < 0.0001$ ).

Normalizing the liver parasite burden of each animal, and expressing this as number of parasites per million human hepatocytes, enables the conduct of comparative studies while using animals with different degrees of chimerism. This is important since the generation of humanized mice is a complex, expensive and time consuming process and the resulting chimeric livers have different degrees of human hepatocyte repopulation.

The data here shows that infected mosquito bites lead to a detectable infection in chimeric mice that is at least as reproducible as IV injection of 150,000 sporozoites



isolated from salivary glands of infected mosquitoes (Additional file 2: Table S2). Using the estimation that one mosquito blood meal results in the injection of up to 500 sporozoites [34], exposure to 20 infected mosquitoes can possibly result in the deposition of  $\pm 10,000$  sporozoites into the skin. This is still 15-fold less than an IV injection of 150,000 sporozoites and 100-fold less than the inoculum ( $10^6$  sporozoites) previously injected by other investigators [14,15]. The results show that an IV injection of 150,000 sporozoites leads only to an average 7.5-fold increase in detected parasites compared to exposure to 20 infected mosquitoes (Additional file 2: Table S2). The cause of this discrepancy is not known, but could be attributed to sporozoites killed during the dissection process.

Therefore the natural infection route for challenge may be preferable to study early events during *P. falciparum* infections for a number of reasons: i) material injected intravenously also contains an undefined amount of debris from the dissection of the salivary glands from the mosquitoes and may compromise success of infection and the ensuing processes; ii) IV injection of sporozoites bypasses a series of natural events (epithelial crossing, skin cell reactivity, etc.) of which the precise biological impact and necessity for hepatocyte recognition and invasion are not yet defined. In this way, possible effects of tested novel compounds or anti-sporozoite antibodies will be missed; and, iii) for the evaluation of agents that may have an effect on sporozoites migration to the liver, the duration of contact prior

to liver invasion can be of importance. This contact time is much longer when sporozoites are deposited in the host's skin by a mosquito bite (minutes) compared to direct deposition in the bloodstream [34,37].

## Conclusions

A protocol was developed to detect and quantify *P. falciparum* parasites to study the therapeutic and/or prophylactic qualities of novel compounds, small molecules or antibodies, in chimeric mice repopulated with human hepatocytes. Apart from being susceptible to human hepatotropic microorganisms these mice also express a humanized drug metabolism [38-42]. This will accelerate and reduce the costs of the development of new strategies to prevent and treat the pre-erythrocytic stage of malaria before these are tested in human volunteers.

## Additional files

**Additional file 1: Table S1.** Analysis of the livers of humanized mice after IV sporozoites injection. Analysis of two infected humanized mice. Panel 1: number of detected parasites in twelve samples (five  $\mu$ L from each) and mean. Panel 2: percentage of human hepatocytes in twelve samples, mean, and percentage repopulation after correction for the percentage of the liver that is made up of hepatocytes. Panel 3: total number of human hepatocytes analysed in each sample, total number human hepatocytes analysed for each mouse, and the liver parasite burden (expressed as the number of parasites per million human hepatocytes) calculated from panel 1 and 3.

**Additional file 2: Table S2.** List of sporozoite injections and mosquito challenges in humanized mice. Twelve mice were infected by intravenous sporozoite injection or by mosquito challenge. Panel 1: human albumin measured by ELISA, percentage repopulation calculated by qPCR, total number of human hepatocytes analysed per mouse, number of parasites in twelve samples (five  $\mu$ L from each), mean, and liver parasite burden (expressed as the number of parasites per million human hepatocytes). Panel 2: for each infection route or both combined: mean weight, mean albumin, mean percentage repopulation, mean number of human hepatocytes analysed, percentage of positive samples for each sampling site in the humanized livers, mean number of parasites in each sample (five  $\mu$ L from each), mean liver parasite burden (expressed as the number of parasites per million human hepatocytes).

## Abbreviations

ELISA: Enzyme-linked immunosorbent assay; Fah: Fumarylacetoacetate hydrolase; FAM: 6-carboxy-fluorescein; FRG:  $Fah^{-/-}Rag2^{-/-}IL2-Rg^{-/-}$ ; GFP: Green fluorescent protein; HBV: Hepatitis B virus; HCV: Hepatitis C virus; huRBC: Human red blood cells; IL2-Rg: Interleukin-2 receptor  $\gamma$  chain; IV: Intravenous; NF54: Nijmegen falciparum strain 54; PBMC: Peripheral blood mononuclear cell; PTGER2: Prostaglandin E receptor 2; qPCR: Quantitative polymerase chain reaction; RAG: Recombination activating gene; SCID: Severe combined immunodeficiency; TAMRA: 6-carboxy-tetramethylrhodamine; uPA: Urokinase plasminogen activator.

## Competing interests

The authors have declared that they have no competing interests.

## Authors' contributions

Conception and design of the experiments: LF, CCH, GJVG, RS, PM, GLR; data acquisition: LF; data analysis: LF, CCH, RS, PM, GLR. All authors contributed to the development of the manuscript, were involved in finalizing the manuscript, all authors read and approved the final manuscript.

## Acknowledgements

We would like to thank Caroline Buysschaert, Jolanda Klaassen, Jacqueline Kuhnén, Laura Pelsers-Posthumus, Astrid Pouwelsen, Marga van de Vegte-Bolmer, Ali Farhoudi and Lieven Verhoye for technical assistance.

## Funding

Research funded by grants provided by the Ghent University (GOA #01G01712) and the Belgian state (IUAP P7/47-HEPRO2); LF is funded by a PhD grant of the Agency for Innovation by Science and Technology (IWT).

## Author details

<sup>1</sup>Center for Vaccinology, Ghent University and University Hospital, De Pintelaan 185, Ghent 9000, Belgium. <sup>2</sup>Medical Centre, Radboud University Nijmegen, Geert Grooteplein 28, GA 6525 Nijmegen, The Netherlands. <sup>3</sup>Department of Pathology, Ghent University and University Hospital, De Pintelaan 185, Ghent 9000, Belgium.

Received: 3 September 2013 Accepted: 10 November 2013

Published: 24 November 2013

## References

1. WHO: *World malaria report 2012*. Geneva: World Health Organization; 2012.
2. Booker ML, Bastos CM, Kramer ML, Barker RH Jr, Skerlj R, Sidhu AB, Deng X, Celatka C, Cortese JF, Guerrero Bravo JE, Crespo Llado KN, Serrano AE, Angulo-Barturen I, Jimenez-Diaz MB, Viera S, Garuti H, Wittlin S, Papastogiannidis P, Lin JW, Janse CJ, Khan SM, Duraisingh M, Coleman B, Goldsmith EJ, Phillips MA, Munoz B, Wirth DF, Klinger JD, Wiegand R, Sybertz E: **Novel inhibitors of *Plasmodium falciparum* dihydroorotate dehydrogenase with anti-malarial activity in the mouse model.** *J Biol Chem* 2010, **285**:33054-33064.
3. Leitner WW, Bergmann-Leitner ES, Angov E: **Comparison of *Plasmodium berghei* challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy.** *Malar J* 2010, **9**:145.
4. Duffy PE, Sahu T, Akue A, Milman N, Anderson C: **Pre-erythrocytic malaria vaccines: identifying the targets.** *Expert Rev Vaccines* 2012, **11**:1261-1280.
5. Macchiarini F, Manz MG, Palucka AK, Shultz LD: **Humanized mice: are we there yet?** *J Exp Med* 2005, **202**:1307-1311.
6. Angulo-Barturen I, Jimenez-Diaz MB, Mulet T, Rullas J, Herreros E, Ferrer S, Jimenez E, Mendoza A, Regadera J, Rosenthal PJ, Bathurst I, Pompliano DL, Gomez De Las Heras F, Gargallo-Viola D: **A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes.** *PLoS One* 2008, **3**:e2252.
7. Jimenez-Diaz MB, Mulet T, Viera S, Gomez V, Garuti H, Ibanez J, Alvarez-Doval A, Shultz LD, Martinez A, Gargallo-Viola D, Angulo-Barturen I: **Improved murine model of malaria using *Plasmodium falciparum* competent strains and non-myelodepleted NOD-scid IL2R $\gamma$ manull mice engrafted with human erythrocytes.** *Antimicrob Agents Chemother* 2009, **53**:4533-4536.
8. Arnold L, Tyagi RK, Meija P, Swetman C, Gleeson J, Pérignon J-L, Druilhe P: **Further improvements of the *P. falciparum* humanized mouse model.** *PLoS One* 2011, **6**:e18045.
9. Meuleman P, Libbrecht L, De Vos R, de Hemptinne B, Gevaert K, Vandekerckhove J, Roskams T, Leroux-Roels G: **Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera.** *Hepatology* 2005, **41**:847-856.
10. Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, Ellis E, Strom S, Kay MA, Finegold M, Grompe M: **Robust expansion of human hepatocytes in  $Fah^{-/-}Rag2^{-/-}Il2rg^{-/-}$  mice.** *Nat Biotechnol* 2007, **25**:903-910.
11. Bissig KD, Le TT, Woods NB, Verma IM: **Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model.** *Proc Natl Acad Sci USA* 2007, **104**:20507-20511.
12. Vanwolleghem T, Libbrecht L, Hansen BE, Desombere I, Roskams T, Meuleman P, Leroux-Roels G: **Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice.** *J Hepatol* 2010, **53**:468-476.
13. Tateno C, Miya F, Wake K, Kataoka M, Ishida Y, Yamasaki C, Yanagi A, Kakuni M, Wisse E, Verheyen F, Inoue K, Sato K, Kudo A, Arai S, Itamoto T, Asahara T, Tsunoda T, Yoshizato K: **Morphological and microarray analyses of human hepatocytes from xenogeneic host livers.** *Lab Invest* 2013, **93**:54-71.



14. Sacci JB Jr, Alam U, Douglas D, Lewis J, Tyrrell DL, Azad AF, Kneteman NM: **Plasmodium falciparum infection and exoerythrocytic development in mice with chimeric human livers.** *Int J Parasitol* 2006, **36**:353–360.
15. Vaughan AM, Mikolajczak SA, Wilson EM, Grompe M, Kaushansky A, Camargo N, Bial J, Ploss A, Kappe SH: **Complete Plasmodium falciparum liver-stage development in liver-chimeric mice.** *J Clin Invest* 2012, **122**:3618–3628.
16. Vaughan AM, Kappe SH, Ploss A, Mikolajczak SA: **Development of humanized mouse models to study human malaria parasite infection.** *Future Microbiol* 2012, **7**:657–665.
17. Meuleman P, Leroux-Roels G: **The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV.** *Antiviral Res* 2008, **80**:231–238.
18. Bukh J, Meuleman P, Tellier R, Engle RE, Feinstone SM, Eder G, Satterfield WC, Govindarajan S, Krawczynski K, Miller RH, Leroux-Roels G, Purcell RH: **Challenge pools of hepatitis C virus genotypes 1–6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models.** *J Infect Dis* 2010, **201**:1381–1389.
19. Meuleman P, Bukh J, Verhoye L, Farhoudi A, Vanwolleghem T, Wang RY, Desombere I, Alter H, Purcell RH, Leroux-Roels G: **In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus.** *Hepatology* 2011, **53**:755–762.
20. Meuleman P, Teresa Catanese M, Verhoye L, Desombere I, Farhoudi A, Jones CT, Sheahan T, Grzyb K, Cortese R, Rice CM, Leroux-Roels G, Nicosia A: **A Human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.** *Hepatology* 2012, **55**:364–372.
21. Sacci J, Schrieffer M, Resau J, Wirtz R, Detolla L, Markham R, Azad A: **Mouse model for exoerythrocytic stages of Plasmodium falciparum malaria parasite.** *Proc Natl Acad Sci USA* 1992, **89**:3701–3706.
22. Vaughan A, Mikolajczak S, Camargo N, Lakshmanan V, Kennedy M, Lindner S, Miller J, Hume JC, Kappe S: **A transgenic Plasmodium falciparum NF54 strain that expresses GFP-luciferase throughout the parasite life cycle.** *Mol Biochem Parasitol* 2012, **186**:143–147.
23. Ploemen IH, Prudencio M, Douradinha BG, Ramesar J, Fonager J, van Gemert GJ, Luty AJ, Hermsen CC, Sauerwein RW, Baptista FG, Mota MM, Waters AP, Que I, Lowik CW, Khan SM, Janse CJ, Franke-Fayard BM: **Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging.** *PLoS One* 2009, **4**:e7881.
24. Meuleman P, Vanlandschoot P, Leroux-Roels G: **A simple and rapid method to determine the zygosity of uPA-transgenic SCID mice.** *Biochem Biophys Res Commun* 2003, **308**:375–378.
25. Ponnudurai T, Lensen AH, Van Gemert GJ, Bensink MP, Bolmer M, Meuwissen JH: **Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes.** *Parasitology* 1989, **98**(Pt 2):165–173.
26. Yoeli M, Upmanis RS, Vanderberg J, Most H: **Life cycle and patterns of development of Plasmodium berghei in normal and experimental hosts.** *Mil Med* 1966, **131**(Suppl):900–914.
27. Yardeni T, Eckhaus M, Morris H, Huizing M, Hoogstraten-Miller S: **Retro-orbital injections in mice.** *Lab Anim (NY)* 2011, **40**:155.
28. Hermsen CC, Telgt DS, Linders EH, van de Loch LA, Eling WM, Mensink EJ, Sauerwein RW: **Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR.** *Mol Biochem Parasitol* 2001, **118**:247–251.
29. Alcoser SY, Kimmel DJ, Borgel SD, Carter JP, Dougherty KM, Hollingshead MG: **Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenografts.** *BMC Biotechnol* 2011, **11**:124.
30. Dufour JF, Clavien PA: *Signaling pathways in liver diseases.* Heidelberg: Springer; 2010.
31. Meuleman P, Libbrecht L, de Vos R, Roskams T, Leroux-Roels G: **Cytopathic effects of hepatitis B virus infection in long-term infected chimeric uPA-SCID mice.** *Hepatology* 2004, **40**:267a.
32. Marcos R, Monteiro RA, Rocha E: **Design-based stereological estimation of hepatocyte number, by combining the smooth optical fractionator and immunocytochemistry with anti-carcinoembryonic antigen polyclonal antibodies.** *Liver Int* 2006, **26**:116–124.
33. Sauerwein RW, Roestenberg M, Moorthy VS: **Experimental human challenge infections can accelerate clinical malaria vaccine development.** *Nat Rev Immunol* 2011, **11**:57–64.
34. Jin Y, Kebaier C, Vanderberg J: **Direct microscopic quantification of dynamics of plasmodium berghei sporozoite transmission from mosquitoes to mice.** *Infect Immun* 2007, **75**:5532–5539.
35. Garnham PCC: *Malaria parasites and other haemosporidia.* Oxford: Blackwell Scientific; 1966.
36. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, Asahara T, Yokoi T, Furukawa T, Yoshizato K: **Near completely humanized liver in mice shows human-type metabolic responses to drugs.** *Am J Pathol* 2004, **165**:901–913.
37. Vanderberg J, Frevert U: **Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes.** *Int J Parasitol* 2004, **34**:991–996.
38. Lootens L, Meuleman P, Pozo OJ, Van Eenoo P, Leroux-Roels G, Delbeke FT: **uPA<sup>+/+</sup>-SCID mouse with humanized liver as a model for in vivo metabolism of exogenous steroids: methandienone as a case study.** *Clin Chem* 2009, **55**:1783–1793.
39. Pozo OJ, Van Eenoo P, Deventer K, Lootens L, Van Thuyne W, Parr MK, Schanzer W, Sancho JV, Hernandez F, Meuleman P, Leroux-Roels G, Delbeke FT: **Detection and characterization of a new metabolite of 17alpha-methyltestosterone.** *Drug Metab Dispos* 2009, **37**:2153–2162.
40. Yoshizato K, Tateno C: **In vivo modeling of human liver for pharmacological study using humanized mouse.** *Expert Opin Drug Metab Toxicol* 2009, **5**:1435–1446.
41. Strom SC, Davila J, Grompe M: **Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity.** *Meth Mol Biol* 2010, **640**:491–509.
42. De Serres M, Bowers G, Boyle G, Beaumont C, Castellino S, Sigafos J, Dave M, Roberts A, Shah V, Olson K, Patel D, Wagner D, Yeager R, Serabjit-Singh C: **Evaluation of a chimeric (uPA<sup>+/+</sup>)/SCID mouse model with a humanized liver for prediction of human metabolism.** *Xenobiotica* 2011, **41**:464–475.

doi:10.1186/1475-2875-12-430

**Cite this article as:** Foquet *et al.*: Molecular detection and quantification of Plasmodium falciparum-infected human hepatocytes in chimeric immune-deficient mice. *Malaria Journal* 2013 **12**:430.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

